SLC5A2 and acute kidney injury: Current guidelines, for example, suggests caution in the use of SGLT2i when there is a situation predisposing to AKI and that it should be temporarily suspended to avoid potential adverse events.5,6 However, there seems to be some understanding recently that SGLT2i may have a role even during an episode of AKI, and more importantly the delay in reintroducing SGLT2 inhibitors may be detrimental to the patient.